05-d m-4.03
|
|
|
- ひろと こいまる
- 5 years ago
- Views:
Transcription
1 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS (51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM
2 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb
3 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 53 ) 1 ABPM ITCZ ABPM ABPA Aspergillus steroid ABPA steroid Aspergillus fungus ball old TB steroid ABPA steroid ITCZ steroid WARK ABPA 1 ABPA ITCZ IgE ABPA ITCZ Cochrane Database 2 65 placebo 1. ITCZ
4 54( 54 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 2. ITCZ IgE 1 66 X steroid, Salmeterol theophylline X mucoid impaction Aspergillus itraconazole X ITCZ X ITCZ itraconazole steroid itraconazole CT 3 ITCZ 3. itraconazole itraconazole itraconazole IgE itraconazole IgE Aspergillus IgE 4
5 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 55 ) ABPA A. fumigatus ABPA itraconazole Aspergillus ITCZ Aspergillus IgE 5 steroid steroid 2 steroid steroid itraconazole IgE Aspergillus itraconazole 60 IgE ABPA steroid Predonine itraconazole Predonine 5 mg, itraconazole 100 mg 1 ITCZ itraconazole Predonine Predonine ABPA steroid itraconazole Aspergillus X Predonine itraconazole Predonine IgE Aspergillus Predonine
6 56( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb ABPA steroid 2 steroid steroid fluticasone itraconazole 3 steroid itraconazole 100 mg Predonine steroid itraconazole 2 steroid IgE Aspergillus IgE Aspergillus steroid 2 steroid itraconazole fluticasone itraconazole IgE IU/ml A. terreus Aspergillus ABPA Predonine itraconazole steroid X 6 CT CT itraconazole 200 mg 50 mg
7 Feb. ITCZ 27 ABPA itraconazole steroid steroid itraconazole Aspergillus Predonine IgE Aspergillus ITCZ 3 IgE 2 3 ITCZ Aspergillus Aspergillus THE JAPANESE JOURNAL OF ANTIBIOTICS ( 57 ) 200 mg 100 mg 200 mg mg steroid Aspergillus steroid steroid Aspergillus itraconazole ABPA ABPA
8 58( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. IgE Aspergillus ABPA fungus ball IgE steroid IgE Aspergillus CT Aspergillus ABPA ABPA ABPA
9 Feb. 100 mg 200 mg THE JAPANESE JOURNAL OF ANTIBIOTICS ( 59 ) mg 200 mg 400 mg
10 60( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 2 ABPA ITCZ Itraconazole Amphotericin B, Ketoconazole ABPA 90 Itraconazole Itraconazole ABPA 400 mg 200 mg 16 New England Journal of Medicine Steroid ABPA 2 3 JACI Steroid mg ABPA Cystic fibrosis Steroid Steroid Early intervention
11 Feb. 3 Itraconazole ABPA ABPA Itraconazole 3 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 61 ) 15 ABPA 21 ABPA Itraconazole 15 2 Itraconazole 15 2 Steroid DM Itraconazole 100 mg DM 12 Itraconazole Itraconazole Itraconazole 200 mg (1) 2. (2)
12 62( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 3. 1, stage III 4. 3, 55 4 stage I III ABPA Itraconazole Steroid 1 Itraconazole 6 24 Itraconazole ABPA Steroid hit & way IgE kg Itraconazole 100 mg IgE 3 IgE 3000 Itraconazole 1 Steroid Itraconazole 1 Predonine Flutide 1 IgE Aspergillus Itraconazole 1
13 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 63 ) 5. (1) 6. (2) Predonine 10 Steroid Itraconazole mg 100 mg 1 hit & way 5, 6 Itraconazole ABPA Itraconazole Itraconazole Steroid Steroid Steroid Steroid Itraconazole Itraconazole Itraconazole Steroid Steroid
14 64( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. Itraconazole Aspergillus ITCZ 1 Aspergillus Steroid Steroid Itraconazole Steroid IgE IgE IgE Itraconazole 5 ABPA 30 Steroid Itraconazole ABPA Steroid Steroid Steroid
15 Feb ABPA 3 IgE Steroid Itraconazole IgE IgE IgE IgE IgE THE JAPANESE JOURNAL OF ANTIBIOTICS ( 65 ) IgE 1 TBLB CT IgE IgE Th2 cytokine 2 Itraconazole ABPA ABPM Steroid Itraconazole
16 66(66) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 3 ABPA WBC 12% CRP IgE 3525 IgE Aspergillus Aspergillus 1 M. ayium DDH PCR Aspergillus fumigatus Aspergillus 1 CT 2 Mucoid impaction 3 Aspergillus fumigatus
17 Feb. 4 CRP CRP ABPA Predonine 30 mg Itraconazole 200 mg CRP IgE Steroid 15 mg Fluticasone 400 Steroid 10 mg 5 CT 6 4. THE JAPANESE JOURNAL OF ANTIBIOTICS (67) M. avium 10 Itraconazole 20 Fluticasone WBC 5300 CRP Zovirax CRP Itraconazole 100 mg Predonine 20 mg IgE 6. 5.
18 68(68) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb IgE 500 ABPA 4 2 Steroid ABPA Beclometasone 3 ABPA 500 mg 250 mg 3 3 Fluconazole Beclometasone Fluconazole ABPA ABPA ABPA 9 4 Steroid Itraconazole Steroid Bedesonide 2 Steroid Fluticasone 400 Steroid Fluticasone Steroid Itraconazole Steroid Steroid Itraconazole 10 ABPA 23
19 Feb. ABPA Itraconazole Steroid Steroid THE JAPANESE JOURNAL OF ANTIBIOTICS (69) 2 Steroid Fluticasone 800 Mucoid impaction Itriaconazole Steroid Steroid Steroid
20 70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. ABPM Allergic bronchopulmonary aspergillosis (ABPA) 1952 HINSON X SCADDING ABPA X ABPA 1977 ROSENBERG Aspergillus IgE ABPA aspergilloma ABPA ABPA Penicillium Helminthosporium ABPA Allergic bronchopulmonary mycosis (ABPM) Allergic bronchopulmonary fungal disease (ABPFD) ROSENBERG ABPA
21 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 71 ) 2. ABPA/M 3. ABPA/M KATZENSTEIN ABPA (mucoid impaction of bronchi; MIB) bronchocentric granulomatosis (BrCG) JOLIHOFSKY ABPA 1988 BOSKEN ABPM Bronchocentric granulomatosis (BrCG_Eo) MIB ABPM ABPM ABPM ABPM BOSKEN 6 3
22 72( 72 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb ROSENBERG 1 1 B 9 a HE Charcot-Leyden 3b JOLIHOFSKY (fir-tree structure) 3a 4
23 Feb. BrCG_Eo 5a BrCG_Eo 5b THE JAPANESE JOURNAL OF ANTIBIOTICS ( 73 ) 6a, 6b
24 74( 74 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb BrCG_Eo 2 BOSKEN ROSENBERG KATZENSTEIN ABPA ABPA ABPM ABPM 7 ABPM 3 i) ii) ABPA/M 5. ABPA/M ABPM ABPM ROSENBERG ABPA ABPM ABPM ABPM ABPM 5 i) ii) iii) ABPM
25 Feb. 6. (17 8 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 75 ) ROSENBERG 1 ROSENBERG ABPM ROSENBERG ROSENBERG 4 3 Aspergillus 1 6 8a 8b 9a Charcot-Leyden 9b TBLB 8 3 ROSENBERG ABPM 7 i) ABPM ii) ABPM iii)
26 76( 76 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb TBLB ABPA/M ROSENBERG ABPM 8 casts Casts 11a casts 11b Charcot-Leyden 12a,b ABPM casts casts Casts
27 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 77 ) 13. casts 1.5 mm 3.0 mm 13 casts ABPM casts 8 i) ABPM ii) ABPM iii) ABPM Aspergillus 6 Bronchocentric granulomatosis Bronchocentric granulomatosis ABPA
28 78( 78 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. ABPM plug BCG plug plug ABPA CT ABPA Asthmatic
29 Feb. Aspergillus Aspergillus THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79 ) ABPM ABPM ABPM Steroid
30 80( 80 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. ABPM ABPA ABPA Aspergillus ABPA Steroid Itraconazole ABPA ABPA Aspergillus Aspergillus ABPA Itraconazole Aspergillus Aspergillus Aspergillus Aspergillus Aspergilloma Aspergillus Aspergillus Aspergillus Itraconazole IDSA EORTC IDSA Aspergillus Aspergilloma ABPA Aspergillus Itraconazole Aspergilloma Itraconazole ABPA Steroid Aspergilloma Itraconazole mg 400 mg Amphotericin B Micafungin Micafungin mg Amphotericin B mg/kg 1 Itraconazole 300 mg mg 5 Aspergilloma
31 Feb. 1. ITCZ THE JAPANESE JOURNAL OF ANTIBIOTICS ( 81 ) 2. Aspergilloma Itraconazole 3700 ng/ml 1 Itraconazole 1000 ng/ml Aspergilloma Itraconazole IDSA Itraconazole Apergilloma 300 mg 1 Aspergillus Itraconazole Itraconazole 2 Itraconazole mg Itraconazole Amphotericin B mg/kg/day Itraconazole Flucytosine Micafungin mg Aspergillus Aspergillus Aspergillus Aspergillus Amphotericin B Flucytosine 3 Itraconazole Aspergillus Amphotericin B Amphotericin B Fluconazole Amphotericin B Itraconazole Amphotericin B Itraconazole
32 82( 82 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb Micafungin Aspergillus fumigatus 4. A. fumigatus 6. Micafungin Aspergillus fumigatus micafungin 4 Itraconazole Amphotericin B Micafungin Itraconazole Aspergillus Amphotericin B Itraconazole 5 Micafungin Itraconazole Amphotericin B Micafungin Itraconazole 6 ABPA Itraconazole ABPA Aspergilloma ABPA Aspergillus IgE CT Aspergilloma 2 33 ABPM IgE Aspergillus IgE 88% IgE X
33 Feb. 30% 60% 60% 1 Aspergilloma 1 Steroid 2 5mg IgE Steroid Itraconazole Steroid ABPA Placebo Itraconazole IgE Itraconazole Itraconazole 400 mg 16 ABPA Steroid Itraconazole Prednisolone Aspergillus Triazole Voriconazole Aspergillus Posaconazole Itraconazole (1Æ3)-b -D-glucan Micafungin 12 Amphotericin B Micafungin 73 Aspergillus PCR Micafungin 150 mg X THE JAPANESE JOURNAL OF ANTIBIOTICS ( 83 ) CT Micafungin Aspergillus Micafungin Itraconazole Micafungin 150 mg 77 Itraconazole 200 mg X Aspergillus Micafungin Amphotericin B 5.0 C.I. 2.1 C.I. Voriconazole 3 Aspergillus 68.2% Aspergilloma % Aspergillus % Aspergillus % Aspergillus 7 Amphotericin B Amphotericin B 7.
34 84( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. Itraconazole Voriconazole Echinocandins Caspofungin Micafungin Aspergillus Voriconazole Candida Caspofungin Micafungin Voriconazole Itraconazole Aspergillus ABPA Aspergillus ABPA ABPA Itraconazole Steroid Steroid Itraconazole QOL Amphotericin B Itraconazole 2 Amphotericin B Itraconazole ATL Aspergillus Aspergillus Micafungin Amphotericin B Itraconazole Aspergilloma Aspergilloma ABPA ABPM Steroid ABPA
35 Feb. Amphotericin B Aspergillus Aspergillus Aspergillus Aspergillus Aspergillus THE JAPANESE JOURNAL OF ANTIBIOTICS ( 85 ) ABPM ABPA Itraconazole 200 mg 200 mg 400 mg ABPA X Aspergillus
36 86( 86 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 4 9 ABPA ABPA ABPA 3 ABPA Aspergillus 10 Itraconazole 3 12
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I
Feb. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 37 37 Liposomal amphotericin B 1 2 2 2 1 1 1 2 1 1 2 2012 12 25 33 Lymphangioleiomyomatosis: LAM 2 20xx 1 CT Aspergillus spp. Micafungin MCFG Itraconazole
A A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6
ほんぶん－第６章.indd
m,m ...,,,..... BCG - /.... T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
日本化学療法学会雑誌第58巻第2号
Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
-Vol.88.3／前.indd
_ NinJa NinJa NinJa NinJa Table NinJa NinJa NinJa Fig. 1 Fig. 2 NinJa NinJa NinJa M.abscessus M.abscessus M.abscessus M. avium M.avium M.intracellulare M. abscessus Mycobacterium avium Fig. M.tuberculosis
8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
Ｋ Ｓｅｒｖｅｒ ４４ 新潟県厚生農業協同組合 本文 ５７ ４ ５巻 ７ 号 ７ ２ の Eosinophil EOSI は でアレルギーを疑う所 見 で あ っ た Aspergillus 抗 原 Aspergillus 抗 体 β-d Glucan Candida 抗原は陰性で その他の項目は
Ｋ Ｓｅｒｖｅｒ ４４ 新潟県厚生農業協同組合 本文 ５７ ４ ７ 喀痰のグラム染色所見とコロニーの染色所見より Schizophyllum commune スエヒロタケ 感染症による ５巻 号 ７ ２ アレルギー性気管支肺真菌症 allergic bronchopulumonary mycosis, ABPM が 最も疑われた症例 症例報告 喀痰のグラム染色所見とコロニーの染色所見より Schizophyllum
により IgG 抗体も産生されⅠ 型アレルギーだけでなくⅢ 型 IV 型アレルギー反応も来す疾患とされている 1) 喘息患者に特有の粘稠な喀疾と閉塞した気道中に Af が定着増殖し 患者がアトピー素因を有するため Af 特異的 IgE 抗体が産生されⅠ 型アレルギー機序により喘息が増悪する また I
肺アスペルギルス症 ( 特にアレルギー性気管支肺アスペルギルス症 )(151127) 症例の勉強会で最終診断が肺アスペルギルス症であった 肺アスペルギルス症について復習 肺アスペルギルス症は空中浮遊真菌であるアスペルギルス属の経気道的侵入によって生じる肺疾患の総称で 呼吸器科が扱う真菌症の中でも頻度の高い疾患である 1) 欧米においては 全人口の約 1% が真菌の吸入により呼吸器症状を呈すると考えられている
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
untitled
( ) 200133 3 3 3 3, 7 347 57 10 i ii iii -1- -2- -3- -4- 90011001700mm -5- 4.2 1991 73.5 44.4 7.4 10.5 10.5 7.4 W 3 H 2.25 H 2.25 7.4 51.8 140.6 88.8 268.8m 5,037.9m 2 2mm 16cm916cm 10.5 W 3 H 2.25 62.8
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
★索引.indb
S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in
当初セフトリアキソン (CTRX) 投与にて改善なく 細菌学的検査陰性より器質化肺炎と診断し PSL30mg/ 日で治療開始した しかし炎症反応ならびに肺浸潤影の増悪を認め クリプトコッカス抗原陽性より真菌症の合併と考え フルコナゾール (FLCZ)400mg/ 日を開始した 炎症反応 画像所見に軽
症例検討間質性肺炎合併 RA 患者で空洞形成を来した症例 国立病院機構九州医療センター膠原病内科末松栄一 (2015 年第 16 回博多リウマチセミナー ) 関節リウマチ (RA) 患者は間質性肺炎を始め 呼吸器疾患を合併することが多い その中でも空洞形 成を来した場合 確定診断ならびに治療方針の判断に苦慮することがある 今回経過中に肺の空洞病変 を認めた RA 症例を経験したので経過を含めて報告する
...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
untitled
7 ( ). 1. 2. 3. 4. 5. 6. . 1. (C.difficile associated disease CDAD) 1) CDAD 60 72 2 CDAD Toxin CDAD 2) (1) C.difficile C.difficile (2) C.difficile (toxin A toxin B) toxin A toxin B (A+B+) toxin A toxin
13,825,228 3,707,995 26.8 4.9 25 3 8 9 1 50,000 0.29 1.59 70,000 0.29 1.74 12,500 0.39 1.69 12,500 0.55 10,000 20,000 0.13 1.58 30,000 0.00 1.26 5,000 0.13 1.58 25,000 40,000 0.13 1.58 50,000 0.00 1.26
１
10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17
BIT -2-
2004.3.31 10 11 12-1- BIT -2- -3-256 258 932 524 585 -4- -5- A B A B AB A B A B C AB A B AB AB AB AB -6- -7- A B -8- -9- -10- mm -11- fax -12- -13- -14- -15- s58.10.1 1255 4.2 30.10-16- -17- -18- -19-6.12.10
日本化学療法学会雑誌第50巻新薬特集号
micafungin in vitro 3 3 micafungin Candida Aspergillus Candida albicans fluconazole Candida tropicalis, Candida glabrata, Candida krusei Aspergillus 90 MIC90 0. g ml amphotericin B fluconazole itraconazole
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
VOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
（個別のテーマ） 薬剤に関連した医療事故
- 67 - III - 68 - - 69 - III - 70 - - 71 - III - 72 - - 73 - III - 74 - - 75 - III - 76 - - 77 - III - 78 - - 79 - III - 80 - - 81 - III - 82 - - 83 - III - 84 - - 85 - - 86 - III - 87 - III - 88 - - 89
（個別のテーマ） 放射線検査に関連した医療事故
- 131 - III - 132 - - 133 - III - 134 - - 135 - III - 136 - - 137 - III - 138 - - 139 - III - 140 - - 141 - III - 142 - - 143 - III - 144 - - 145 - III - 146 - - 147 - III - 148 - - 149 - III - 150 - -
EV200R I II III 1 2 3 4 5 6 7 8 9 10 1 2 3 11 4 5 12 6 13 1 2 14 3 4 15 5 16 1 2 17 3 18 4 5 19 6 20 21 22 123 456 123 456 23 1 2 24 3 4 25 5 3 26 4 5 6 27 7 8 9 28 29 30 31 32 1 2 33 3 4 34 1 35 2 1
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書
1... 1 2... 3 I... 3 II... 3 1.... 3 2....15 3....17 4....19 5....25 6....34 7....38 8....48 9....58 III...70 3...73 I...73 1....73 2....82 II...98 4...99 1....99 2....104 3....106 4....108 5.... 110 6....
商学５７‐５／１．山村
217 1982 1998 2002 14 7 7 250 3 2 2004 16 2004 a 90 218 1 1 1948 23 25 19 2004 47 3 13 2 14 1969 2 25 25 20 21.1 70 34.5 40 219 50 25 2004 1kg1 l 1,000 mg1 g 250 mg 1mg 1mg 1 mg 19 1911 44 2005 25 50 1498
ニトロトルエン
4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6
第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11
untitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58
23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23
untitled
i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)
平成１８年度「商品先物取引に関する実態調査」報告書
... 1.... 5-1.... 6-2.... 9-3.... 10-4.... 12-5.... 13-6.... 15-7.... 16-8.... 17-9.... 20-10.... 22-11.... 24-12.... 27-13... 29-14.... 32-15... 37-16.... 39-17.... 41-18... 43-19... 45.... 49-1... 50-2...
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
ひとくちメモ/山口英世先生
Epidemiology of antifungal resistance : current status and future perspective Hideyo YAMAGUCHI 2 4 6 4 9 4 MCZ MCFG 7 4 MRSA Candida spp. MCZ a B b MCFG P45 4αCYP5 c DNA d CYP5 CYP5,3-D-,3-D-,3-D- a b
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
ありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
ネットショップ・オーナー２ ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
05[ ]戸田(責)村.indd
![05[ ]戸田(責)村.indd](/thumbs/91/106164845.jpg "05[ ]戸田(責)村.indd")
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
防衛関係費／防衛関係費
29 6 24 5,063,717,069 4,826,454,531! 4,713,781,797 " 212,416,621 $$ # % & "!# $ 10,759,902 123,445,947 8,593,004 52,891,392! 8,593,004 59,925,253 " # $ % 7,033,861 & # $ % 2,070,900 71,136,937 & 99,743,887
